Inhibikase president forfeits 338,282 shares

Inhibikase Therapeutics executive Cabell Christopher reported the forfeiture of 338,282 shares of common stock back to the company.

Rhea-AI Filing Summary

Inhibikase Therapeutics executive Cabell Christopher reported the forfeiture of 338,282 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition completed on February 21, 2025, but were subject to a milestone that had to be met by the first anniversary of that closing date.

On February 21, 2026, the milestone was determined not to have been achieved, causing all 338,282 shares to be returned to the issuer for no consideration. Following this disposition to the issuer, Christopher directly holds 676,564 shares of Inhibikase common stock.

Insider Trade Summary

Disposition: 338,282 shares

Disposition 1 txn

Insider Cabell Christopher

Role President & Head of R&D

Type	Security	Shares	Price	Value
Disposition	Common Stock	338,282	$0.00	$0.00

Holdings After Transaction: Common Stock — 676,564 shares (Direct)

Footnotes (1)

1. F1. As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Inhibikase Therapeutics (IKT) report for Cabell Christopher?

Inhibikase Therapeutics reported that executive Cabell Christopher forfeited 338,282 shares of common stock back to the company. The disposition was recorded at a price of $0.0000 per share, reflecting that he received no cash or other consideration in return.

Why were 338,282 Inhibikase (IKT) shares forfeited by Cabell Christopher?

The 338,282 shares were originally issued as merger consideration in the CorHepta Pharmaceuticals acquisition and were subject to a milestone. When that milestone was not achieved by February 21, 2026, all of those shares were forfeited back to Inhibikase, with no consideration paid.

How many Inhibikase (IKT) shares does Cabell Christopher own after the forfeiture?

After the forfeiture of 338,282 shares, Cabell Christopher directly holds 676,564 shares of Inhibikase common stock. This amount reflects his reported beneficial ownership following the issuer disposition that occurred on February 21, 2026, as disclosed in the insider transaction data.

Was the Inhibikase (IKT) insider transaction a sale in the open market?

The transaction was not an open-market sale. It was classified as a disposition to the issuer, triggered by a milestone linked to the CorHepta acquisition not being achieved, and the reporting person received no consideration from Inhibikase for the forfeited 338,282 shares.

How is the CorHepta Pharmaceuticals acquisition linked to this Inhibikase (IKT) Form 4?

Cabell Christopher received Inhibikase shares as merger consideration when the CorHepta Pharmaceuticals acquisition closed on February 21, 2025. A portion, 338,282 shares, was subject to milestone-based forfeiture, which occurred one year later when that milestone was not met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 08:53 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cabell Christopher

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Head of R&D

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/21/2026		D		338,282(1)	D	$0	676,564(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

	/s/ Mark Iwicki, attorney-in-fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.